文献速递免疫规划传染病防控与疫情报告

在新加坡成人中接种单剂四价登革热疫苗(两种不同血清型2效价)的安全性与免疫原性:一项2期双盲随机对照试验

Safety and immunogenicity of a single dose of a tetravalent dengue vaccine with two different serotype-2 potencies in adults in Singapore: A phase 2, double-blind, randomised, controlled trial.
PubMed 文献 · Vaccine · 2019-12-13

在新加坡21-45岁成人中开展的2期双盲随机对照试验,按基线登革热血清状态分层后1:1随机接受单剂HD-TDV或TDV(血清型2效价低10倍)。两组总体不良事件率相似,TDV在基线血清阴性者中诱导更均衡的免疫应答。

要点

  • 两组针对所有血清型的几何平均滴度峰值均出现在第30天,且针对DENV-2的滴度最高。
  • 基线血清阴性者中,TDV组第30天DENV-2几何平均滴度为813,HD-TDV组为10966。
  • TDV组病毒血症发生率低于HD-TDV组,且主要在第30天前消退。

核心结论

  • 结果提示,与早期配方HD-TDV相比,新配方TDV诱导更均衡的免疫应答,尤其在接种前血清阴性者中,并支持选择新配方用于3期效力评估。

研究设计与样本

  • 在新加坡开展的2期双盲随机对照试验,纳入21-45岁成人,按基线登革热血清状态分层后1:1随机接受单剂HD-TDV或TDV。
  • 共351例受试者随机分组,其中176例接受HD-TDV,175例接受TDV。

主要发现

  • 两组针对所有血清型的几何平均滴度峰值均出现在第30天,且两组针对DENV-2的几何平均滴度最高。
  • 在基线血清阴性者中,针对DENV-2的应答在TDV组中较不占优势:第30天几何平均滴度TDV组为813,HD-TDV组为10966。
  • 在基线血清阴性者中,TDV组的DENV-4血清阳性率和几何平均滴度均高于HD-TDV组:第30天几何平均滴度TDV组为58,HD-TDV组为21;血清阳性率TDV组为76%,HD-TDV组为60%。
  • 两组病毒血症均主要针对TDV-2,且TDV接种者中病毒血症发生率较低,多数在第30天前消退。
  • 两种疫苗配方均显示可接受的安全性特征,两组征集性和非征集性不良事件总体发生率相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Early formulations of Takeda's tetravalent dengue vaccine candidate (TAK-003) have demonstrated notably higher neutralizing antibody responses against serotype 2 than other serotypes. Here, we assessed the immunogenicity and tolerability in adults living in Singapore of two TAK-003 formulations: an early formulation, referred to as HD-TDV, and a new formulation with 10-fold lower serotype 2 potency, referred to as TDV (NCT02425098). METHODS: Subjects aged 21-45 years were stratified by baseline dengue serostatus and randomised 1:1 to receive a single dose of either HD-TDV or TDV. Immunogenicity was evaluated at Days 15, 30, 90, 180, and 365 post-vaccination as geometric mean titres (GMTs) of neutralising antibodies and seropositivity rates. Viremia was assessed per vaccine strain. Solicited and unsolicited adverse events (AEs) were assessed by severity and causality. RESULTS: Of 351 subjects randomised, 176 received HD-TDV and 175 received TDV. Peak GMTs against all serotypes were observed at Day 30, with highest GMTs against DENV-2 in both groups. In subjects seronegative at baseline, the response to DENV-2 was less dominant with TDV (Day 30 GMTs: 813 for TDV, 10,966 for HD-TDV). In these subjects, DENV-4 seropositivity rates and GMTs were higher with TDV (Day 30 GMTs: 58 for TDV, 21 for HD-TDV; seropositivity rates: 76% for TDV, 60% for HD-TDV). Viremia mainly occurred for TDV-2 in both vaccine groups, with a lower incidence in TDV recipients, and mostly resolved by Day 30. Both vaccine formulations showed an acceptable safety profile with similar overall rates of solicited and unsolicited AEs across vaccine groups. CONCLUSIONS: These results suggest a more balanced immune response with the new formulation TDV compared with the early formulation HD-TDV, particularly in subjects who were seronegative prior to vaccination, and support the choice of the new formulation for the phase 3 efficacy assessment.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Tricou V, Low JG, Oh HM, et al. Safety and immunogenicity of a single dose of a tetravalent dengue vaccine with two different serotype-2 potencies in adults in Singapore: A phase 2, double-blind, randomised, controlled trial. Vaccine. 2019. PMID: 31843269. doi:10.1016/j.vaccine.2019.11.061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。